Stephen David Prior - Nov 4, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Strategy Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Stephen David Prior
Stock symbol: ANTX
Transactions as of: Nov 4, 2024
Transactions value $: $0
Form type: 4
Date filed: 11/5/2024, 04:57 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Award	$0	+10.1K	+40.15%	$0.00	35.3K	Nov 4, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANTX	Stock Option (right to buy)	Award	$0	+20.3K		$0.00	20.3K	Nov 4, 2024	Common Stock	20.3K	$1.08	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of Restricted Stock Units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, subject to the Reporting Person's continuous service as of such date.
F2	Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3	The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date.